AMETEK, Inc. (AME) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup leans toward a beat — consensus sits at the low end of management's Q2 guidance range, the record $3.87B backlog provides strong revenue visibility, and the Indicor acquisition adds incremental EPS contribution not fully reflected in street estimates; the biggest swing factor is whether organic orders sustained their Q1 momentum through June or showed any deceleration.

The bar heading into Q2 is manageable: consensus adjusted EPS of ~$1.996 sits near the midpoint of management's $1.96–$2.00 guidance range, and revenue consensus of ~$1.959B implies high-single-digit growth consistent with the company's own outlook. Management's tone on the Q1 call was notably confident — record orders of $2.2B (up 23% YoY, organic +22%), a record backlog of $3.87B, and a full-year EPS raise to $7.94–$8.14 all signaled strong execution momentum. Estimate revisions have been essentially flat since the Q1 print (Q2 EPS moved from $1.994 to $1.996 over the past 12 weeks), suggesting the street has largely digested the guidance raise without adding incremental optimism — a setup that historically favors upside surprises for AMETEK. The stock has traded roughly in line with XLI since the April 30 earnings date (+3.4% vs. +4.9% for XLI through August 1), implying the market has not pre-priced a significant beat. The key wildcard is the Indicor Instrumentation acquisition: announced May 6 and financed with $7.5B in new credit facilities secured June 9, the deal's closing timeline and any preliminary financial contribution could surprise the market, while the associated leverage step-up (from ~1x to potentially 3–4x gross debt/EBITDA) will be a focus for investors assessing the balance sheet impact on future M&A capacity.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar — estimates sit near the midpoint of guidance and have barely moved since the Q1 print, leaving room for upside. Orders and organic growth are the bigger swing factors; a repeat of Q1’s record order momentum would be the most powerful positive catalyst, while any deceleration would pressure the stock despite an EPS beat.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data — Net Sales, Adj. EPS, Organic Growth, Orders, Operating Margin, Free Cash Flow. Q2 2026 guidance from AME Q1 2026 Earnings Call (April 30, 2026).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Adj. EPS & Net Sales)

Pattern: AMETEK has beaten adjusted EPS consensus in 7 of the last 8 quarters, with an average positive surprise of ~+3.5%; the one revenue miss (Q1 2025) coincided with the trough of the industrial cycle and is not representative of the current demand environment. The consistent beat pattern, combined with management’s historically conservative guidance, supports a bias toward upside on the Q2 print.

Sources: Visible Alpha Consensus and Actuals Data.

Table 3 — Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 EPS moved only +$0.002 and revenue barely changed — suggesting the street has not added incremental optimism beyond management’s guidance. This flat revision trajectory is a cushion, not a risk: any organic order or margin upside would likely drive meaningful estimate upgrades post-print.

Sources: Visible Alpha Consensus and Actuals Data (revision history weekly series, May 8 – August 3, 2026). FY 2026 consensus of $8.158 sits above the guidance midpoint of $8.04, consistent with the street embedding a modest beat assumption into the full-year number.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been raised once since the last earnings call (full-year EPS lifted to $7.94–$8.14 from $7.87–$8.07 on April 30) and has not been revised since; the only material post-earnings development is the transformative Indicor acquisition announced May 6, which will require updated guidance on the Q2 call. Management tone remains confident but deliberately prudent given geopolitical uncertainty.

4. Stock Performance Since Last Earnings (April 30 – August 3, 2026)

Key Takeaway: AME has lagged XLI since the Q1 earnings print despite strong fundamental execution, suggesting the market is applying a modest discount for Indicor acquisition uncertainty and leverage step-up; the 12-month +31.9% gain was driven predominantly by multiple expansion (+15.8% on EV/EBITDA), not earnings growth alone.

Source: Stock Price Data (Yahoo Finance). Indexed to April 30, 2026 close (AME: $235.50, XLI: $174.58, SPY: $718.66). August 3, 2026 close: AME $241.71, XLI $179.84, SPY $747.03.

Performance Narrative: AME opened the post-earnings period strongly, rallying to $241 by May 6 on the Indicor acquisition announcement, then pulled back to a trough of ~$221 by May 19 as the market digested the scale of the deal and associated leverage. The stock recovered through June, reaching a new high of ~$242 by June 30, before consolidating in the $231–$244 range through July. The 12-month performance decomposition shows that ~15.8% of the +31.9% total return came from EV/EBITDA multiple expansion (from 18.1x to 21.0x NTM), with the remainder from earnings growth — suggesting the stock is not cheap heading into the print at ~31x NTM P/E. Key events during the period: (1) May 6: Indicor acquisition announced; (2) May 8: Nick Stanage appointed independent director; (3) June 9/12: $7.5B credit facilities secured (revolving credit expanded to $3.5B + $4.0B term loan), replacing bridge financing.

5. Material News & Developments Since Q1 Earnings (April 30, 2026)

Key Takeaway: The Indicor acquisition is the dominant development — it is transformative in scale, materially changes the balance sheet, and will require updated guidance on the Q2 call; investors will focus on deal timing, leverage trajectory, and whether the acquisition is accretive to the FY 2026 EPS range.

• May 6, 2026 — Indicor Instrumentation Acquisition Announced: AMETEK signed a definitive agreement to acquire a portfolio of instrumentation businesses from Indicor, LLC. No purchase price was disclosed in the 8-K. The deal is strategically significant, expanding AMETEK’s process and analytical instrumentation capabilities within EIG. Implication: This is the largest announced deal in recent AMETEK history; the Q2 call will be the first opportunity for management to provide financial details (purchase price, revenue contribution, EPS accretion/dilution, and closing timeline). Consensus does not yet reflect any Indicor contribution.
• May 8, 2026 — Nick Stanage Appointed Independent Director: AMETEK added Nick L. Stanage (former Hexcel CEO) to its board. Implication: Positive signal for governance and aerospace/advanced materials expertise; no financial impact.
• June 9–12, 2026 — $7.5B Credit Facilities Secured: AMETEK entered into an Amended and Restated Revolving Credit Agreement ($3.5B, up from $2.3B, maturing June 2031) and a new $4.0B Term Loan Agreement (three tranches: $1.625B at 3 years, $1.625B at 4 years, $750M at 5 years) to fund the Indicor acquisition. The $5.0B bridge financing commitment was simultaneously terminated. Implication: Leverage will step up materially from the current ~1x gross debt/EBITDA; management will need to articulate a deleveraging path. The term loan structure (SOFR + spread) introduces meaningful interest expense headwinds not yet in consensus estimates.
• April 30, 2026 — First Aviation Services Acquisition Announced (concurrent with Q1 earnings): AMETEK signed a definitive agreement to acquire First Aviation Services, a defense MRO provider with ~$80M in annual sales and 6 U.S. centers of excellence. Approximately two-thirds MRO services, one-third proprietary parts. Implication: Bolt-on deal consistent with AMETEK’s A&D aftermarket strategy; likely closed or near closing by Q2 report date. Modest revenue/EPS contribution.
• Ongoing — Tariff & Macro Environment: Management stated on the Q1 call that they expect to offset all inflationary costs including tariffs with pricing. Multiple peers (Eaton, Dover, IDEX, Crane) reported IIPA tariff refunds in Q2 2026 that provided one-time margin benefits; AMETEK may have similar exposure. Implication: Tariff refunds could be a modest upside surprise to Q2 margins if AMETEK received similar IIPA refunds; management will likely address this on the call.
• Ongoing — Indicor Acquisition Financing Overhang: The scale of the Indicor deal ($7.5B in credit facilities implies a purchase price likely in the $5–6B range) represents a significant departure from AMETEK’s typical bolt-on M&A strategy. Implication: Investors will scrutinize the deal’s strategic rationale, margin profile of acquired businesses, and management’s confidence in deleveraging to investment-grade levels within a reasonable timeframe.

6. Insider Transaction Activity

Key Takeaway: Insider activity since the Q1 earnings print is minimal and unremarkable — one routine disposition by the CAO (likely tax-related) and one grant to a newly appointed director. No open-market buys or discretionary sales; no clustered selling that would signal concern.

Source: Insider Transaction Data (SEC Form 4 filings). No open-market buys or discretionary sales were filed in the period. The absence of insider selling ahead of a transformative acquisition announcement is consistent with normal pre-announcement blackout protocols.

7. Peer Commentary: Current-Quarter Read-Throughs (Q2 2026)

Key Takeaway: Peer commentary from Q2 2026 earnings calls (reported July 23–July 31) is broadly positive for AMETEK’s key end markets — aerospace & defense, process instrumentation, power/data center, and medical — with multiple peers raising full-year guidance. The most relevant read-throughs come from Eaton (power/A&D), Dover (A&D components, process), IDEX (instrumentation, semiconductor, life sciences), Crane (A&D, process), and Graco (industrial/semiconductor). Nordson (reported May 21) provides an earlier-quarter read on semiconductor and medical trends.

Methodology: Only commentary from the last 60 days (June 3 – August 3, 2026) that addresses Q2 2026 conditions, current-quarter demand, or forward outlook communicated after peers’ last earnings is included. Commentary solely about prior-quarter results without forward relevance is excluded.

Eaton Corporation (ETN) — Q2 2026 Earnings Call, July 31, 2026

Read-Through Direction: Positive for AME’s Aerospace & Defense and Power end markets.

• Aerospace demand remains strong and durable: Eaton reported 7% organic sales growth in Aerospace in Q2 2026, with record quarterly sales and record segment profit. Book-to-bill expanded to 1.2x. Management stated demand “remains strong in aerospace, with robust orders driving backlog expansion… resulting in higher sales growth with attractive margins” and expects this to continue “into the foreseeable future.” AME relevance: AMETEK’s A&D segment (~18% of sales, guided to ~10% organic growth for FY 2026) should benefit from the same broad-based commercial OEM and defense demand Eaton is seeing. Eaton’s aerospace book-to-bill of 1.2x is a strong leading indicator for AMETEK’s own A&D orders.
• Power/electrical demand accelerating broadly: Eaton raised total organic growth guidance by 200 bps to 11–13% for FY 2026, driven by data center, commercial, and industrial electrical demand. Electrical Americas book-to-bill expanded to 1.3x; negotiations pipeline up 60% YTD. Total US data center backlog grew to 307GW (15 years of backlog at 2025 build rates). AME relevance: AMETEK’s Power subsegment (guided to mid-single-digit organic growth) serves data center microgrids, power generation, and backup power — directly aligned with Eaton’s demand commentary. Eaton’s record order momentum is a positive read-through for AMETEK’s power-related businesses.
• Tariff/pricing: IIPA tariff refunds in Q2 were less than $3M for Eaton (immaterial, <$0.01 EPS) and are already embedded in H2 guidance. Pricing actions taken in Q2 and early Q3 expected to return price-cost to roughly neutral in H2. AME relevance: Suggests AMETEK’s own tariff offset strategy (pricing to cover inflation) is consistent with peer experience; any IIPA refunds at AMETEK would be upside.
• Caveat: Eaton’s electrical business is more directly exposed to data center infrastructure than AMETEK; the magnitude of Eaton’s order growth may not translate 1:1 to AMETEK’s more diversified portfolio.

Dover Corporation (DOV) — Q2 2026 Earnings Call, July 23, 2026

Read-Through Direction: Positive for AME’s A&D components, process instrumentation, and biopharma end markets.

• Broad-based order momentum with book-to-bill of 1.06x: Dover reported 5% organic growth in Q2 2026 with all five segments posting positive organic growth. Orders increased 16% YoY, with consolidated trailing 12-month bookings up 15%. Management raised full-year adjusted EPS guidance, citing “demand signals remain constructive across the portfolio.” AME relevance: Dover’s broad-based order strength across industrial, A&D, and process end markets is a positive read-through for AMETEK’s similarly diversified portfolio.
• A&D components and power generation infrastructure showing “particular strength”: Dover highlighted aerospace and defense components for steam and gas turbines as secular growth priorities where “demand is outpacing supply and extending lead times.” The company is actively expanding capacity in these areas. AME relevance: Directly positive for AMETEK’s EIG aerospace and defense businesses, which serve similar precision component markets.
• Biopharma/medical performing well on consumable demand: Dover’s single-use biopharma connectors, pumps, and flow meters “continue to benefit from investment behind new therapies, increasing production rates and secular shift toward single-use batch manufacturing.” New product introductions driving share gains. AME relevance: Positive read-through for AMETEK’s medical segment (~20%+ of sales), which includes Paragon Medical and Record businesses. Dover’s commentary supports AMETEK’s mid-single-digit medical growth guide for FY 2026.
• Polymer processing (process instrumentation analog) exited Q2 with book-to-bill above 1.0x: Dover noted polymer processing had a tough Q2 but exited with book-to-bill >1.0x, signaling “stabilization and a better outlook for that longer cycle business” into 2027. AME relevance: Consistent with AMETEK’s own process business recovery narrative (guided to low-to-mid single-digit organic growth for FY 2026).
• Caveat: Dover’s CO2 refrigeration business had execution issues in Q2 (facility consolidation/labor ramp) that are idiosyncratic and not relevant to AMETEK.

IDEX Corporation (IEX) — Q2 2026 Earnings Call, July 29, 2026

Read-Through Direction: Positive for AME’s instrumentation, semiconductor, data center, and life sciences end markets.

• Record orders of over $1B; HST organic orders +47% YoY: IDEX reported 28% organic order growth in Q2 2026, with Health and Science Technology (HST) leading at +47%. Order growth was driven by data center, semiconductor, and space & defense markets, which now represent over a third of HST revenue. Management raised FY 2026 organic growth guidance to 5–6% (from 3–4%) and raised adjusted EPS guidance to $8.70–$8.85. AME relevance: AMETEK’s EIG instrumentation businesses (process, power, semiconductor) serve overlapping end markets. IDEX’s record order momentum in precision instrumentation and semiconductor-adjacent applications is a strong positive read-through for AMETEK’s EIG organic orders in Q2.
• Short-cycle industrial orders inflecting positive in late Q2 and into July: IDEX CEO noted that “classic up-and-down-the-street, small order flow” business — a bellwether for the broader industrial economy — began inflecting positive in June and continued into July. “We’re encouraged by both sides firing” (secular growth markets + traditional short-cycle). AME relevance: This is a meaningful positive read-through for AMETEK’s process and automation businesses, which have been recovering from a 2024–2025 trough. If short-cycle industrial demand is genuinely inflecting, AMETEK’s Q2 orders could surprise to the upside.
• Life sciences/analytical instruments showing early positive momentum: IDEX noted that its core fluidics business (analytical instruments, liquid chromatography) moved from low-single-digit to mid-single-digit growth rates in Q2, with some backlog build in life sciences. “We do think [this] is a positive sign.” AME relevance: Positive read-through for AMETEK’s medical and analytical instrumentation businesses within EIG.
• Fastest-growing customers prebooking capacity further into the future: IDEX noted customers in data center and semiconductor markets are “submitting orders with request dates further into the future, primarily to prebook capacity,” with twice the 2027 business set up at mid-year vs. the same point last year. AME relevance: Supports AMETEK’s record backlog narrative and suggests the order book quality is improving, not just the quantity.
• Caveat: IDEX’s tariff refunds (IIPA) provided a $0.08 EPS benefit in Q2 that is largely confined to Q2; AMETEK may or may not have similar exposure. IDEX’s FMT segment (more traditional industrial) saw only +1% organic sales growth, a reminder that not all industrial sub-segments are recovering equally.

Crane Company (CR) — Q2 2026 Earnings Call, July 29, 2026

Read-Through Direction: Positive for AME’s Aerospace & Defense and process flow end markets.

• A&AT segment delivered 13% core sales growth in Q2 2026: Crane’s Aerospace and Advanced Technologies segment led with 13% core sales growth, driven by “broad-based strength across both commercial aerospace and defense markets.” Backlog reached a record of nearly $1.3B, with core YoY backlog growth of 11% and sequential core backlog growth of 7%. Management raised full-year A&AT core sales growth guidance to “just above the high end of our long-term 7–9% range.” AME relevance: Directly positive for AMETEK’s A&D segment. Crane’s record A&D backlog and raised guidance reinforce AMETEK’s own ~10% A&D organic growth target for FY 2026.
• Missile defense demand expanding 4–5x by end of decade: Crane noted ~$35M in current missile program content across 10+ programs, with RFP activity and customer forecasts suggesting a 4–5x expansion “through the end of the decade.” No capacity constraints. AME relevance: AMETEK has broad-based defense exposure including UAV programs, missile defense, and naval/submarine platforms. Crane’s missile demand commentary is a strong positive read-through for AMETEK’s defense businesses.
• Commercial aftermarket expected to continue at mid-to-upper-single-digit rates: Crane expects commercial aftermarket to “continue in the mid-single to upper mid-single rate” for the balance of 2026 and into 2027. Commercial and military OE sales were up double digits in Q2. AME relevance: Positive for AMETEK’s MRO businesses (including the newly acquired First Aviation Services) and commercial aerospace OE exposure.
• Process Flow Technologies (PFT) expects positive YoY growth in H2 2026: Crane’s PFT segment (process flow equipment) delivered a second consecutive quarter of sequential core backlog growth and expects to “turn positive growth on a year-over-year basis in the second half.” Chemical production in the Americas is “a new green spot.” Cryogenics momentum strong (SpaceX, Blue Origin orders). AME relevance: Positive read-through for AMETEK’s process instrumentation businesses, which are also recovering. Crane’s H2 inflection in process flow is consistent with AMETEK’s low-to-mid single-digit process organic growth guide.
• Acquisitions outperforming: Crane’s recent acquisitions are “outperforming” with synergies realized “faster than anticipated” and EPS contribution raised from $0.15 to $0.20 per share for FY 2026. AME relevance: Positive precedent for AMETEK’s own acquisition integration track record (FARO, Paragon) and potentially for Indicor.
• Caveat: Crane’s PFT core sales were down 1.4% in Q2 (though backlog is building), a reminder that process recovery is still uneven quarter-to-quarter.

Graco Inc. (GGG) — Q2 2026 Earnings Call, July 23, 2026

Read-Through Direction: PositiveMixed for broader short-cycle industrial.

• Semiconductor bookings +58% in Q2 2026; 6-week average +36%: Graco’s Expansion Markets (semiconductor) saw bookings increase 58% in Q2, with the most recent 6-week average up 36% and backlogs remaining strong. CEO stated semiconductor “should last through the end of this year, and I would guess into next year as well.” AME relevance: Positive read-through for AMETEK’s semiconductor-exposed businesses within EIG (Abaco, materials analysis). Graco’s semiconductor momentum is consistent with AMETEK’s own commentary about semiconductor strength.
• Industrial orders improving but still mixed: Graco’s Industrial segment saw organic orders improve throughout Q2, with bookings up 3% YTD through July 17 and up 11% in the most recent 6-week period. PMI turning positive. MRO channels “pretty healthy.” AME relevance: Consistent with AMETEK’s process and automation recovery narrative, though Graco’s industrial exposure is more consumer/manufacturing-oriented than AMETEK’s mission-critical niche markets.
• Contractor segment 6-week order trend +14%: Graco’s Contractor segment (construction/infrastructure) saw 6-week order trends improve to +14% YoY, driven by infrastructure spending and data center construction. AME relevance: Indirect positive for AMETEK’s power and automation businesses serving infrastructure markets.
• Tariff refunds provided $9M gross margin benefit in Q2: Graco received $9M in IIPA tariff refunds (net of related surcharges) in Q2, which provided a “meaningful benefit” to gross margins. Price-cost remains positive at ~1.5–2% realized pricing. AME relevance: Suggests AMETEK may also have received IIPA tariff refunds in Q2; if so, this would be a modest upside to reported margins.
• Caveat: Graco’s Contractor segment had been in a multi-year downturn and is only now recovering; the 14% 6-week trend may reflect easy comps rather than a broad industrial acceleration. Graco’s business mix (fluid handling, spray equipment) is less directly comparable to AMETEK’s precision instrumentation focus.

Ingersoll Rand (IR) — Q2 2026 Earnings Call, July 31, 2026

Read-Through Direction: Mixed for AME’s process and industrial end markets; positive for life sciences.

• Short-to-medium cycle orders up mid-single digits in Q2; long-cycle projects delayed but recovering: Ingersoll Rand reported organic order growth of 2% and organic revenue growth of 4% in Q2 2026. Short-to-medium cycle business saw orders up mid-single digits, while several large long-cycle project orders were delayed (primarily in European blower/vacuum and Middle East). July saw double-digit order growth (low double-digit to mid-teens organic) as delayed long-cycle orders materialized. AME relevance: The short-cycle improvement is a positive read-through for AMETEK’s process businesses. The long-cycle delay/recovery pattern is consistent with AMETEK’s own process recovery narrative.
• Life sciences (biopharma/GLP-1) delivering low double-digit organic order growth: IR’s Life Sciences segment delivered “low double-digit organic order growth” in Q2, largely driven by biopharma and GLP-1 exposure. Investments in larger biopharma expansion expected to create potential for H2 2026 and 2027. AME relevance: Positive read-through for AMETEK’s medical segment, particularly Paragon Medical and Record businesses.
• Americas strongest region; China pricing pressure “transitory”: Americas orders up high single digits; China organic revenue up low double digits but pricing remains “the most challenged market” due to overcapacity. IR characterized China pricing pressure as “transitory.” AME relevance: AMETEK’s China business was up high-teens in Q1 2026 (process and power markets). IR’s China pricing commentary is a mild caution, though AMETEK’s China exposure is more niche/mission-critical and less susceptible to commoditized pricing pressure.
• IIPA tariff refunds excluded from guidance as “upside”: IR explicitly excluded IIPA tariff refunds from its H2 2026 adjusted EBITDA and EPS guidance, treating them as upside. AME relevance: If AMETEK received similar refunds, they could be a modest Q2 margin tailwind not in consensus.
• Caveat: IR’s Q2 adjusted EBITDA margin declined 160 bps YoY due to China pricing pressure and higher corporate costs — a reminder that not all industrial companies are seeing margin expansion. AMETEK’s more differentiated, niche positioning should insulate it from similar pressures.

Nordson Corporation (NDSN) — Q2 FY2026 Earnings Call, May 21, 2026

Read-Through Direction: Positive for AME’s semiconductor, medical, and industrial automation end markets. (Note: Nordson’s fiscal Q2 ended April 30, 2026; commentary addresses conditions during AMETEK’s Q2 2026 reporting period and forward outlook.)

• Record sales of $741M; 7% organic growth; backlog up 18% organically YoY: Nordson reported record Q2 sales with “accelerated activity in the last couple of months” driving 18% organic backlog growth. All three segments achieved record Q2 sales. Management entered Q3 with “strong order entry and increased backlog.” AME relevance: Nordson’s accelerating order momentum in late April/early May (which falls within AMETEK’s Q2 2026 period) is a positive read-through for AMETEK’s own Q2 order trends.
• Semiconductor “in the early stages” of the cycle; ATS backlog up double digits: Nordson’s Advanced Technology Solutions (semiconductor) segment achieved an all-time quarterly record with 8% organic growth. Management stated they are “in the early stages” of the semiconductor cycle, with test and inspection businesses “beginning to inflect.” Over 50% of ATS revenue is now in semiconductor. AME relevance: Positive read-through for AMETEK’s semiconductor-exposed businesses (Abaco, materials analysis). The “early stages” characterization suggests the cycle has runway, supporting AMETEK’s semiconductor growth through 2026 and into 2027.
• Medical returning to normalized growth of 6–8%: Nordson’s Medical and Fluid Solutions segment delivered 8% organic growth in Q2, with management stating medical is “on track and still returning to normal growth rates of what we would call 6% to 8% as a target.” Medical order entry and backlog buildup provide confidence in normalized growth. AME relevance: Positive read-through for AMETEK’s medical segment. Nordson’s 6–8% normalized growth target is consistent with AMETEK’s mid-single-digit medical guide for FY 2026.
• Industrial precision solutions returning to normalized growth: Nordson’s IPS segment delivered 5% organic growth in Q2, with management noting “we have returned to normalized growth” and seeing “confidence in system orders.” Packaging, plastics, and industrial coating businesses “certainly improving.” AME relevance: Positive read-through for AMETEK’s automation and engineered solutions businesses.
• Tariff environment: “Not material” but part of broader inflationary backdrop: Nordson noted tariffs “in itself are not material” but are part of a “broader inflationary impact” being managed through “selective pricing” and “offsetting cost actions.” AME relevance: Consistent with AMETEK’s own tariff offset strategy; no incremental concern.
• Caveat: Nordson’s fiscal Q2 ended April 30, 2026 (the same day as AMETEK’s Q1 earnings), so this commentary reflects conditions at the start of AMETEK’s Q2 period. The forward guidance (Q3 FY2026 sales of $760–$790M) is the more relevant forward read-through.

Peer Commentary Summary Table

8. Key Questions for the Q2 2026 Earnings Call

Key Takeaway: The call will be dominated by Indicor acquisition details — purchase price, financial profile, and updated guidance — but investors will also scrutinize whether Q1’s record order momentum was sustained through June and whether management’s tariff offset confidence held in practice.

1. Indicor Acquisition — Financial Details & Updated Guidance: What is the purchase price, revenue run-rate, and EBITDA margin of the Indicor instrumentation businesses? Is the deal accretive or dilutive to FY 2026 EPS, and by how much? What is the expected closing date? How does management plan to delever from the ~3–4x gross leverage implied by the $7.5B credit facilities, and over what timeframe?
2. Q2 Orders — Did the Record Momentum Continue? Q1 2026 organic orders were up 22% YoY (record $2.2B). Did Q2 sustain double-digit organic order growth, or did the comparison base and macro uncertainty cause deceleration? Was the book-to-bill above 1.0x? Did EIG orders continue to inflect positively after Q1’s 25% organic order growth?
3. Organic Growth Trajectory — Process & EIG: Process organic sales were up low-single digits in Q1. Did the momentum continue in Q2, and is management still comfortable with the low-to-mid single-digit full-year process guide? What is the EIG organic growth rate in Q2 (Q1 was only +2% organic despite strong orders)?
4. Margin Performance — Core Incrementals & IIPA Tariff Refunds: Q1 core incrementals were above 50%. Did Q2 maintain similar leverage? Did AMETEK receive any IIPA tariff refunds in Q2 (as peers Eaton, Dover, IDEX, Graco all did), and if so, how are they being treated in adjusted results?
5. FY 2026 Guidance Update: Will management raise the FY 2026 EPS range above $7.94–$8.14 to reflect Q2 performance and/or Indicor contribution? What is the updated organic sales growth expectation for the full year?
6. Balance Sheet & Capital Allocation Post-Indicor: With gross leverage stepping up materially, what is the priority for free cash flow — debt repayment or continued bolt-on M&A? Is the $5B+ M&A capacity statement still valid, or has Indicor effectively consumed the near-term M&A budget?
7. China & Geopolitical Exposure: China was up high-teens in Q1 (process and power). Did this momentum continue in Q2, or did geopolitical uncertainty and trade policy create headwinds? What is the current status of the ~$15M in Middle East orders that did not ship in Q1?
8. First Aviation Services — Closing Status: Has the First Aviation Services acquisition closed? What is the initial revenue and margin contribution, and how is it integrating with AMETEK’s existing MRO businesses?

Disclosures & Data Sources

This document is prepared for informational purposes only and does not constitute investment advice. All financial data is sourced from the following:

• Visible Alpha Consensus and Actuals Data — KPI consensus estimates, actuals, revision history (Net Sales, Adj. EPS, Organic Growth, Orders, Operating Margin, Free Cash Flow). All VA-sourced figures are as of August 3, 2026.
• Stock Price Data (Yahoo Finance) — AME, XLI, SPY daily closing prices, April 30 – August 3, 2026.
• SEC EDGAR / Insider Transaction Data — Form 4 filings for AME insiders (May 2026).
• AME SEC Filings — 8-K filings dated May 6, 2026 (Indicor acquisition announcement), May 8, 2026 (director appointment), June 12, 2026 (credit facilities).
• AME Q1 2026 Earnings Release & Transcript — April 30, 2026.
• Peer Earnings Call Transcripts — ETN (July 31, 2026), DOV (July 23, 2026), IEX (July 29, 2026), CR (July 29, 2026), GGG (July 23, 2026), IR (July 31, 2026), NDSN (May 21, 2026).